Psoriatic Arthritis

This retrospective study from Japan highlighted several key elements linked to a generalized pustular psoriasis diagnosis among individuals with psoriasis vulgaris.

This small study found DNA methylation profiles in CD4+ T-cells may represent a stable and reliable biomarker.

Significantly greater improvements in back pain and morning stiffness were observed in patients receiving ixekizumab compared with placebo.

Continued reductions in serum acute phase proteins and collagen degradation proteins observed in patients with psoriatic arthritis receiving guselkumab may be linked to sustained symptom improvements.

An interim analysis from the UPJOINT trial provides insight into the effects of upadacitinib use in real-world settings among patients with oligo- or polyarticular psoriatic arthritis.

Investigators believe a more consistent application of disease activity measures may help to guide treatment decisions and improve quality of care.

A higher number of patients receiving guselkumab treatment reported ≥1 improvement as early as week 4, which continued to improve through week 24.

Real-world analyses help patients and their healthcare providers make more informed and personalized treatment decisions with the goal of long-term symptomatic relief.

At week 24, patients receiving guselkumab had significant decreases in C-reactive protein and effector cytokines linked to the interleukin-23 (IL-23)/IL-17 levels compared with patients in the placebo cohort.

Researchers report on the global real-world safety profile of tofacitinib in psoriatic arthritis.

Findings reveal a need for distinct strategies to prevent cardiovascular events in patients with rheumatoid arthritis and psoriatic arthritis.

At weeks 12 and 24, the proportion of patients reporting high disease activity reduced from 16.7% to 8.3%, respectively.

This systematic review found 26 DMARDs in clinical development for spondyloarthritis, including psoriatic arthritis, but their target diversity was low.

According to the PRESTO tool, the risk of developing psoriatic arthritis in patients with psoriasis within 1 year was linked to a family history of psoriasis, joint or back stiffness, male sex, younger age, pain severity, and the use of biologic medications.

Changes in BMI were positively correlated with changes in IL-23 and significant positive correlations were observed between BMI and DAS28-CRP, CRP, IL-13, IL-17, leptin, and TNF-α.

Patients with JPsA and concomitant psoriasis at diagnosis exhibited more depressive symptoms when compared with those without psoriasis.

In the updated analysis, the interleukin-23 p19-subunit inhibitor also showed better skin efficacy.

Women with psoriatic arthritis reported higher mean pain and worse mean patient global assessment when compared with men.

In this Q&A, Andrew Östör, MD, discussed the findings of a study that evaluated the one-year efficacy and safety of risankizumab in patients with inadequate response/intolerance to biologics or conventional synthetic DMARDs.

At week 52, 58.5% of patients continuing risankizumab treatment and 55.7% of patients who switched to risankizumab at week 24 achieved ACR20.

Adam Dore, DO, discusses the recent developments in treating psoriatic arthritis and his predictions for the advancement of care in the upcoming year.

Etanercept was effective at 6 months of follow-up and remained so at 12 months, with low rates of adverse events.

Serum levels of BD-2 at baseline were shown to be significantly linked with subsequent clinical response in patients with psoriatic arthritis.

Celastrol may regulate core target proteins to alleviate the inflammatory response.

Guselkumab was able to provide minimal disease activity improvements from baseline through week 48 in adult patients with psoriatic arthritis.

Patients with unrestful sleep had significantly reduced health-related quality of life and significantly more depressive symptoms.

While most patients were interested in an online wellness program for managing their psoriatic arthritis, barriers, such as cost and fatigue, hindered their initiation of lifestyle adaptations.

More than 90% of respondents reported being “somewhat likely” or “very likely” to speak with an online coach ≥2 per week or spend 1 – 2 hours per week learning about lifestyle behaviors if given the opportunity.

Over a 3-year period, patients treated with upadacitinib reported greater disease improvements and a greater mean change from baseline when compared with those receiving adalimumab.

An analysis of data from the phase 4 MOSAIC trail is providing clinicians with a greater understanding of the effects of apremilast in people with uncontrolled psoriatic arthritis.